Mythology of Diagnostics of Sepsis and Septic Shock in Acute Pneumonia

Igor Klepikov*

MD, Professor, Retired, Renton, WA, USA

*Corresponding Author: Igor Klepikov, MD, Professor, Retired, Renton, WA, USA.

Received: May 26, 2025; Published: October 30, 2025

Abstract

The successful appearance in medical practice of antibiotics, which are exclusively etiotropic agents, has concentrated professional attention on the etiological direction of treatment of non-specific inflammations with the loss of attention to their pathogenesis. The narrow antimicrobial action of antibiotics, which does not affect such a basis of inflammatory processes as the mechanisms of their development, strangely enough, has not been subjected to a logical revision of therapeutic principles, having turned over the years into the dominant worldview. The so-called microbial concept of inflammatory diseases of non-specific etiology, despite the gradual accumulation of facts contradicting it, has formed a deeply rooted conviction in the exceptional role and indispensability of antibiotics in the treatment of such pathology. Misconceptions in the interpretation of the nature of inflammatory processes are especially clearly noticeable in the analysis of examination and treatment materials for patients with acute pneumonia. One of the illustrative examples of the existing deformation of professional views on the nature of this disease is the distorted diagnosis of sepsis and septic shock in acute pneumonia, which entails an inadequate approach to providing medical care.

 Keywords: Acute Inflammation; Nonspecific Etiology; Antibiotics; Pathogenesis; Sepsis; Septic Shock; Acute Pneumonia; Pulmonary Blood Flow Characteristics; Regulation of Blood Circulation

References

1. Burkhart M. “Improving Sepsis Bundle Compliance in the Emergency Department”. The Eleanor Mann School of Nursing Student Works (2021).
2. “Sepsis” (2024).
3. “Sepsis”. Clinical Information. Surveillance and Epidemiology (2018).
4. “Sepsis”. (2024).
5. Fleischmann C., et al. “Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations”. American Journal of Respiratory and Critical Care Medicine 193 (2016): 253-272.
6. Rudd KE., et al. “Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study”. Lancet 395 (2020): 200-211.
7. Vincent JL., et al. “Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis”. Critical Care 23 (2019): 196.
8. Rhee C., et al. “Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals”. JAMA Network Open (2019): 2e187571.
9. Kwan A., et al. “Transcriptional instability during evolving sepsis may limit biomarker based risk stratification”. PLoS One3 (2013): e60501.
10. Iskander KN., et al. “Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding”. Physiology Review3 (2013): 1247-1288.
11. Singer M., et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”. JAMA 8 (2016): 801-810.
12. Vincent JL., et al. “Sepsis in European intensive care units: results of the SOAP study”. Critical Care Medicine 34 (2006): 344-353.
13. Phua J., et al. “Characteristics and outcomes of culture-negative versus culture-positive severe sepsis”. Critical Care 17 (2013): R202.
14. Walden AP., et al. “Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort”. Critical Care 18 (2014): R58.
15. Xiaoying Gu., et al. “Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment”. European Respiratory Review157 (2023): 200038.
16. Lin Lan., et al. “Prognostic accuracy of SOFA, MEWS, and SIRS criteria in predicting the mortality rate of patients with sepsis: A meta-analysis”. Nursing in Critical Care 21 (2023).
17. Póvoa P., et al. “How to use biomarkers of infection or sepsis at the bedside: guide to clinicians”. Intensive Care Medicine 49 (2023): 142-153.
18. Blair PW., et al. “Screening tools for predicting mortality of adults with suspected sepsis: an international sepsis cohort validation study”. BMJ Open 13 (2023): e067840.
19. Schertz AR., et al. “Sepsis Prediction Model for Determining Sepsis vs SIRS, qSOFA, and SOFA”. JAMA Network Open8 (2023): e2329729.
20. Lafon T., et al. “SEPSIGN: early identification of sepsis signs in emergency department”. Internal Emergency Medicine (2024).
21. Robert Gauer., et al. “Sepsis: Diagnosis and Management”. American Family Physician7 (2020): 409-418.
22. Sloan SNB., et al. “Compliance with SEP-1 guidelines is associated with improved outcomes for septic shock but not for severe sepsis”. Journal of Intensive Medicine3 (2022): 167-172.
23. Guarino M., et al. “2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department”. Journal of Clinical Medicine9 (2023): 3188.
24. Beibei Liu and Qingtao Zhou. “Clinical phenotypes of sepsis: a narrative review”. Journal of Thoracic Disease7 (2024).
25. BD Huttner., et al. “COVID-19: don't neglect antimicrobial stewardship principles!” Clinical Microbiology and Infection7 (2020): P808-810.
26. B Beovic., et al. “Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey”. Journal of Antimicrobial Chemotherapy 326 (2020).
27. Rawson TM., et al. “Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing”. Clinical Infectious Disease (2020): ciaa 530.
28. Lipman M., et al. “SARS-CoV-2 pandemic: clinical picture of COVID-19 and implications for research”. Thorax 75 (2020): 614-616.
29. C Georgiou., et al. “Effect of antibiotics efficacy in patients with sepsis and septic shock presenting in the emergency department: A literature review”. Journal of Critical Care 81 (2024).
30. Guo Q., et al. “Contributions of individual qSOFA elements to assessment of severity and for prediction of mortality”. Annals of Medicine1 (2024): 2397090.
31. Dremsizov T., et al. “Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course?” Chest 4 (2006): 968-978.
32. Singer M., et al. “Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation”. Lancet 9433 (2015): 545-548.
33. Angus DC and van der Poll T. “Severe sepsis and septic shock”. NEJM 9 (2013): 840-851.
34. Hotchkiss RS., et al. “Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy”. Nature Reviews Immunology12 (2013): 862-874.
35. Deutschman CS and Tracey KJ. “Sepsis: current dogma and new perspectives”. Immunity4 (2014): 463-475.
36. "What Is Pulmonary Hypertension?". From Diseases and Conditions Index (DCI). National Heart, Lung, and Blood Institute. September (2008).
37. Adair OV. "Chapter 41". Cardiology secrets (2^nd). Philadelphia: Hanley and Belfus (2001): 210.
38. Schwiegk H. “Der Lungenentlastungsreflex”. Pflügers Archiv European Journal of Physiology 236 (1935): 206-219.
39. Klepikov I. “Acute pneumonia and its purulent and destructive complications in children in the midst of a major industrial centre of Western Siberia”. Dissertation for the degree of Doctor of Medical Science. Leningrad, (1989).
40. I Klepikov. “Myths, Legends and Real Facts About Acute Lung Inflammation”. Cambridge Scholars Publishing. 338 (2024).
41. Thillai M., et al. “Functional respiratory imaging identifies redistribution of pulmonary blood flow in patients with COVID-19”. Thorax 76 (2021): 182-184.
42. W Dierckx., et al. “CT-derived measurements of pulmonary blood volume in small vessels and the need for supplemental oxygen in COVID-19 patients”. Journal of Applied Physiology6 (2022): 1295-1299.
43. GW Waterer., et al. “Septic Shock and Respiratory Failure in Community-acquired Pneumonia Have Different TNF Polymorphism Associations”. AJRCCM7 (2001).
44. Sanjay Sethi. “Community-Acquired Pneumonia”. Merck Manual for the Professional (2020).
45. Paula Peyrani., et al. “The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance”. Expert Review of Respiratory Medicine2 (2019): 139-152.
46. Nuala J Meyer and Hallie C Prescott. “Sepsis and Septic Shock”. NEJM 391 (2024): 2133-2146.
47. Sinha P., et al. “Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials”. Lancet Respiratory Medicine 11 (2023): 965-974.
48. Evans L., et al. “Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021”. Critical Care Medicine11 (2021): e1063-e1143.
49. The National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network. NI Shapiro., et al. “Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension”. NEJM (2023).

Citation

Citation: Igor Klepikov. “Mythology of Diagnostics of Sepsis and Septic Shock in Acute Pneumonia”.Acta Scientific Medical Sciences 9.11 (2025): 01-04.

Copyright

Copyright: © 2025 Igor Klepikov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.